Enterprise Value
850.6M
Cash
335.1M
Avg Qtr Burn
-73.25M
Short % of Float
10.21%
Insider Ownership
14.47%
Institutional Own.
-
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Troriluzole Details Spinocerebellar Ataxia | NDA FDA meeting | |
Taldefgrobep alfa Details Spinal muscular atrophy | Phase 3 Data readout | |
Troriluzole Details Obsessive compulsive disorder | Phase 3 Data readout |